share_log

CloudMD Securityholders Approve Go-Private Transaction With CPS Capital

CloudMD Securityholders Approve Go-Private Transaction With CPS Capital

CloudMD股東批准與CPS Capital的私有化交易
GlobeNewswire ·  06/27 23:11

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, is pleased to announce that its securityholders approved the special resolution authorizing the previously announced plan of arrangement (the "Arrangement") with CPS Capital (through an affiliate) (the "Purchaser"). Pursuant to the Arrangement, the Purchaser will, among other things, acquire all of the issued and outstanding common shares of CloudMD ("Shares"). Each CloudMD shareholder (each, a "Shareholder") will receive C$0.04 in cash for each Share held.

CloudMD軟件和服務公司 (TSXV: DOC,法蘭克福: 6PH) (以下簡稱"公司"或"CloudMD")是一家正在改變醫療服務傳遞方式的創新醫療服務公司。公司很高興宣佈,其股東已批准特別決議,授權公司與CPS Capital(通過其附屬公司)(以下簡稱"購買方")進行事先宣佈的安排(以下簡稱"安排")。根據安排,購買方將收購CloudMD的所有普通股(以下簡稱"股份")。CloudMD的每位股東 (以下簡稱"股東") 將獲得每股0.04加元的現金。

The special resolution approving the Arrangement was approved by (i) 69.68% of the votes cast by Shareholders present in person (virtually) or represented by proxy and entitled to vote at the Meeting, (ii) 70.27% of the votes cast by Shareholders and holders of options of CloudMD, voting together as a single class, present in person (virtually) or represented by proxy and entitled to vote at the Meeting, and (iii) 69.60% of the votes cast by Shareholders present in person (virtually) or represented by proxy and entitled to vote at the Meeting other than the votes attached to Shares required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.

股東親自到場(或虛擬)或委託代表到場投票的投票中,贊同安排的特別決議分別佔(i) 股東投票總數的69.68%;(ii) 股東和CloudMD的期權持有人作爲一類投票總數的70.27% ;(iii) 股東親自到場(或虛擬)或委託代表到場投票的投票中,其他所投票數佔股東投票總數的69.60%,此外還有根據61-101多邊協議規定排除的股份的選票數也相應排除。MI 61-101的《保護少數股東特別交易規定》(Protection of Minority Security Holders in Special Transactions)規定,在向MCAPM LP發行債券的情況下,公司可以依靠MI 61-101第5.5(a)和5.7(1)(a)條中規定的從正式估值中豁免,並不要求獲得少數股東批准的豁免規定,因爲債券的公允市場價值低於公司市值的25%(在適用MI 61-101的情況下分別確定)。.

CloudMD will seek a final order of the Supreme Court of British Columbia to approve the Arrangement at a hearing expected to be held on July 3, 2024. The Arrangement is expected to close on or about July 9, 2024, provided all of the customary closing conditions set forth in the definitive agreement are satisfied or waived.

CloudMD將尋求不列顛哥倫比亞省最高法院的終審命令,以批准於2024年7月3日舉行的聽證會上的安排。安排預計於2024年7月9日或前後完成,前提是滿足在明確協議中規定的所有習慣性封閉條件或豁免條件。

Further details regarding the Arrangement can be found in the Company's management information circular dated May 29, 2024 which is filed on SEDAR+ at .

有關安排的進一步詳情可以在公司於2024年5月29日的管理信息循環文件中(在SEDAR+上提交1996386號文件)查閱。

About CloudMD

關於CloudMD

CloudMD is an innovative North American healthcare service provider focused on empowering healthier living by combining leading edge technology with an exceptional national network of healthcare professionals. Every day, our employees and health care providers live our values of delivering excellence, collaboration, connected communication and accountability to solve complex health problems. CloudMD's industry leading workplace health and wellbeing solution, Kii, supports members and their families with a personalized and connected healthcare experience across mental, physical and occupation health. Kii delivers superior clinical health outcomes, consistent high engagement, and measurable ROI for payers such as employers, educational institutions, associations, government, and insurers. CloudMD is also a market leader in workplace absence management through data-driven prevention, intervention and return to work programs.

CloudMD是一家創新的北美保健服務提供商,致力於通過結合領先的科技和優秀的全國醫療保健專業人員網絡,推動更健康的生活。每天,我們的員工和醫療保健提供者都以提供卓越服務、協作、聯繫和問責的價值觀來解決複雜的健康問題。CloudMD行業領先的工作場所健康和福利解決方案Kii,通過精準的心理、身體和職業健康服務,支持會員及其家庭。 Kii爲僱主、教育機構、協會、政府和保險公司等支付方提供卓越的臨床衛生成果、高持久性和可衡量的投資回報率。同時,CloudMD還向醫院、診所和其他保健服務提供商銷售健康和生產力工具,以幫助它們提供更好的護理。訪問以了解有關公司全面的醫療保健服務的更多信息。

In addition, the Company sells health and productivity tools to hospitals, clinics, and other healthcare service providers to empower them to deliver better care. Visit to learn more about the Company's comprehensive healthcare offerings.

此外,公司向醫院、診所和其他醫療服務提供商銷售健康和生產力工具,以幫助他們提供更好的護理服務。訪問 了解公司全面的醫療保健產品。

"Karen Adams"
Chief Executive Officer

"Karen Adams"
首席執行官

FOR ADDITIONAL INFORMATION, CONTACT:

支持和更多信息,請聯繫:

Investor Relations
Investors@cloudmd.ca
1-647-484-1405

投資者關係
Investors@cloudmd.ca
1-647-484-1405

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX創業公司交易所及其監管服務提供方(該術語定義在TSX創業公司政策中)不對此發佈的充分性或準確性承擔任何責任。

Forward Looking Statements

前瞻性聲明

This news release contains "forward-looking statements" and "forward-looking information" within the meaning of Canadian securities laws, including statements relating to the Arrangement, including timing for completion of the Arrangement and receiving the required court approvals. All information that is not clearly historical in nature may constitute forward‐looking statements. In some cases, forward‐looking statements may be identified by the use of terms such as "forecast", "projected", "assumption" and other similar expressions or future or conditional terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will", "would", and "should". Forward-looking statements contained in this news release are based on certain factors and assumptions made by management of CloudMD based on their current expectations, estimates, projections, assumptions and beliefs regarding their business and CloudMD does not provide any assurance that actual results will meet management's expectations. While management considers these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect. Such forward‐looking statements are not guarantees of future events or performance and by their nature involve known and unknown risks, uncertainties and other factors, including those risks described in the Company's MD&A (which is filed under the Company's issuer profile on SEDAR+ and can be accessed at ), that may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking statements. Although CloudMD has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward‐looking statements, other factors may cause actions, events or results to be different than anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could vary or differ materially from those anticipated in such forward‐looking statements. Accordingly, readers should not place undue reliance on forward‐looking information. CloudMD does not undertake to update any forward-looking information, whether as a result of new information or future events or otherwise, except as may be required by applicable securities laws.

本新聞稿包含"前瞻性聲明"和"前瞻性信息",其涉及安排,包括完成安排和獲得所需法院批准的時間。所有不清晰爲歷史性質的信息可能構成前瞻性聲明。在某些情況下,可能會通過使用"預測"、"預計"、"假設"和其他類似表達式,或"預期"、"相信"、"可能"、"估計"、"期望"、"打算"、"計劃"、"預測"、"項目"、"將"、"將要"和"應該"等未來或條件性詞語或類似未來或條件性詞語來識別前瞻性聲明。本新聞稿中包含的前瞻性聲明是基於CloudMD管理層根據其業務和信念的當前期望、估計、投射、假設和信念制定的某些因素和假設,CloudMD不提供任何確保實際結果符合管理層預期的保證。雖然管理層根據當前提供給他們的信息認爲這些假設是合理的,但它們可能被證明是不正確的。此類前瞻性聲明並非未來事件或表現的保證,由於其本質可能包涵已知和未知的風險,不確定性和其他因素,包括該公司的MD&A所描述的那些風險(該公司在SEDAR+上的發行人配置文件下提交該文件,可以通過該文件訪問)。),這可能會導致實際結果、表現或成就與此類前瞻性聲明中表現或暗示的任何未來結果、表現或成就存在實質性差異。雖然CloudMD已盡力確定可能導致實際行動、事件或結果與前瞻性聲明中描述的不同的重要因素,但其他因素可能導致行動、事件或結果與預期、估計或意圖不同。不能保證這些聲明會被證明準確,因爲實際結果和未來事件可能與此類前瞻性聲明中預期的有所不同。因此,讀者不應過分依賴前瞻信息。除非適用的證券法要求,CloudMD不承擔更新任何前瞻性信息的義務。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論